iifl-logo

Biocon Ltd Share Price

326.75
(-2.67%)
Apr 24, 2025|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open334
  • Day's High335
  • 52 Wk High404.7
  • Prev. Close335.7
  • Day's Low325.05
  • 52 Wk Low 269.55
  • Turnover (lac)15,400.03
  • P/E0
  • Face Value5
  • Book Value95.78
  • EPS0.12
  • Mkt. Cap (Cr.)39,229.61
  • Div. Yield0.15
View All Historical Data
Loading...
  • Roll Over%0
  • Roll Cost0
View More Futures

Biocon Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

334

Prev. Close

335.7

Turnover(Lac.)

15,400.03

Day's High

335

Day's Low

325.05

52 Week's High

404.7

52 Week's Low

269.55

Book Value

95.78

Face Value

5

Mkt Cap (₹ Cr.)

39,229.61

P/E

0

EPS

0.12

Divi. Yield

0.15

Biocon Ltd Corporate Action

16 May 2024

12:00 AM

Dividend

Dividend Amount: 0.5

Record Date: 05 Jul, 2024

arrow

20 Apr 2025

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

16 May 2024

12:00 AM

AGM

Announcement Date: 16 May, 2024

arrow

Biocon Ltd NEWS AND UPDATE

Biocon to Raise ₹4,500 Crore; Approves Capital Expansion Plan
24 Apr 2025|09:50 PM

The fundraising may be executed in one or more tranches using QIP, rights issues, or any other permissible route under regulatory guidelines.

Read More
Top Stocks for Today - 24th April 2025
24 Apr 2025|06:20 AM

Here are some of the stocks that may see significant price movement today: LTIMindtree, Dalmia Bharat, Bajaj Housing, etc.

Read More
Biocon unit expands oncology portfolio after USFDA approval
11 Apr 2025|09:00 AM

Jobevne is a vascular endothelial growth factor (VEGF) impediment that sticks with VEGF and restrain the interaction with its receptors.

Read More
Biocon Pharma Gains USFDA Approval for Norepinephrine and Key Therapies
24 Mar 2025|11:51 PM

The first approval is for the 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg strengths of Lenalidomide Capsules.

Read More
Biocon Biologics inks pact with Civica to expand access in US
7 Mar 2025|08:53 AM

Civica will start selling the medicine for patients in the United States after completing development work and clinical trials.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Biocon Ltd SHAREHOLDING SNAPSHOT

25 Apr, 2025|11:21 AM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 20.27%

Foreign: 20.27%

Indian: 40.36%

Non-Promoter- 21.38%

Institutions: 21.38%

Non-Institutions: 17.76%

Custodian: 0.21%

Share Price

Biocon Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Y/e 31 Mar( In .Cr)Mar-2024Mar-2023Mar-2022Mar-2021

Equity Capital

600.3

600.3

600.3

600

Preference Capital

0

0

0

0

Reserves

10,312

10,315.7

7,492.6

7,307.1

Net Worth

10,912.3

10,916

8,092.9

7,907.1

Minority Interest

View Balance Sheet
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Revenue

1,738.2

2,028.4

1,988.4

2,419.2

yoy growth (%)

-14.3

2.01

-17.8

-6.51

Raw materials

-808.2

-798.3

-827.7

-1,049.4

As % of sales

46.49

39.35

41.62

43.37

Employee costs

-367.7

-390.2

-344.8

-408.6

View Profit & Loss
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Profit before tax

139.7

358.8

388.5

305.8

Depreciation

-108.2

-103.5

-98

-136.1

Tax paid

-53.6

-78.3

-111.9

-67.3

Working capital

268.3

64.09

379.5

-311.6

Other operating items

View Cash Flow
Y/e 31 MarMar-2022Mar-2021Mar-2020Mar-2018

Growth matrix (%)

Revenue growth

-14.3

2.01

-17.8

-6.51

Op profit growth

-80.44

9.26

-10.11

-46.23

EBIT growth

-60.99

-7.82

27.02

-43.18

Net profit growth

-69.3

-36.38

84.86

-54.07

View Ratios
Particulars (Rupees in Crores.)Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020

Gross Sales

14,195.8

11,174.2

8,184

7,143.1

6,300.5

Excise Duty

0

0

0

0

0

Net Sales

14,195.8

11,174.2

8,184

7,143.1

6,300.5

Other Operating Income

559.9

0

0

0

0

Other Income

865.5

375.9

212.7

267.1

228.9

Biocon Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceutical Industries Ltd

SUNPHARMA

1,803.9

137.434,32,9601,181.050.755,985.3398.33

Divis Laboratories Ltd

DIVISLAB

6,215.5

79.591,65,003.325940.482,297513.62

Cipla Ltd

CIPLA

1,551.7

26.921,25,285.641,438.150.844,134.87360.73

Torrent Pharmaceuticals Ltd

TORNTPHARM

3,325.1

61.671,12,502.674850.842,330222.38

Mankind Pharma Ltd

MANKIND

2,599.2

55.531,07,385.94416.3802,396.57334.17

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Biocon Ltd

Management

Register Office

Registrar Office

Chairperson

Kiran Mazumdar Shaw

Non Executive Director

Ravi Mazumdar

Lead Independent Director

M Damodaran

Independent Director

Bobby Parikh

Company Sec. & Compli. Officer

Mayank Verma

Managing Director & CEO

SIDDHARTH MITTAL

Non Executive Director

Eric Vivek Mazumdar

Independent Director

Naina Lal Kidwai

Independent Director

Atul Dhawan

Independent Director

Rekha Mehrotra Menon

Independent Director

NICHOLAS ROBERT HAGGAR

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Biocon Limited is Indias largest and fully-integrated, innovation-led biopharmaceutical company. Biocon, with its key business verticals ofGenerics, Biosimilars, Research Services and Novel Biologics, has leveraged its affordable innovation model and scientific capabilities to develop and manufacture both small and large molecules at global scale for the benefit of patients. At present, Company is engaged in the manufacture of biotechnology products and research services. Biocon Limited was incorporated in year 1978 as a joint venture between Biocon Biochemicals Limited of Ireland and an Indian entrepreneur, Kiran Mazumdar-Shaw. Biocon manufactured and exported enzymes to USA and Europe during the year 1979, as first of its kind. In 1989, Unilever plc acquired the Biocon Biochemicals Limited in Ireland and merges it with its subsidiary, Quest International. Also in the same year, the company had received US funding for proprietary technologies. After a year, in 1990, Biocon had scaled up its in-house research programme, based on a proprietary solid substrate fermentation technology, from pilot to plant level. Biocons R&D and manufacturing facilities received ISO 9001 certification from RWTUV, Germany during the period of 1993. In the year 1994, the company had established the Syngene International Pvt. Ltd. as a Custom research Company (CRC) to address the growing need for outsourced R&D in the pharmaceutical sector. The commercial success of Biocons proprietary fermentation
Read More

Company FAQs

What is the Biocon Ltd share price today?

The Biocon Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹326.75 today.

What is the Market Cap of Biocon Ltd?

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Biocon Ltd is ₹39229.61 Cr. as of 24 Apr ‘25

What is the PE and PB ratio of Biocon Ltd?

The PE and PB ratios of Biocon Ltd is 0 and 3.70 as of 24 Apr ‘25

What is the 52 Week High and Low of Biocon Ltd?

The 52-week high/low is the highest and lowest price at which a Biocon Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Biocon Ltd is ₹269.55 and ₹404.7 as of 24 Apr ‘25

What is the CAGR of Biocon Ltd?

Biocon Ltd's CAGR for 5 Years at -0.70%, 3 Years at -4.12%, 1 Year at 19.83%, 6 Month at 3.23%, 3 Month at -15.50% and 1 Month at -3.89%.

What is the shareholding pattern of Biocon Ltd?

The shareholding pattern of Biocon Ltd is as follows:
Promoters - 60.64 %
Institutions - 21.39 %
Public - 17.76 %

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.